A director at Heineken N.V. sold 7,000 shares at 68.000EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 15 December 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 8 December 2025 up to and including 12 December 2025 a total of 182,810 shares were repurchased on exchange at an average price of € 68.36. During the same period, 182,76...
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
The surprise call on the outlook update was only open to analysts and basically served to highlight the past 10 years of growth. Nevertheless €2.30 EPRA EPS, comes above consensus and our €2.25 estimate. Xior wants to show that after 2 years of transition and flat EPS, they will show growth again. Under COO, Kristina Olsen, Xior has also improved its internal operations and budget planning for next year had already finished. The focus is on internal efficiency gains and rental growth from realis...
Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar
Today Xior celebrates its 10 year listing on the Brussels stock exchange. At the same time it issued a FY26 EPRA EPS outlook and expects EPS growth of +4% in FY26 to €2.30 vs. FY25 of €2.21. Xior is confident about the future, driven by its student housing platform and 98% occupancy. It expects rental growth from additions to its scalable operations and structural market scarcity to drive rental increases. Also efficiency gains should add to profitability gains. Xior will focus on portfolio opti...
ASM nominates CEO and SB member for reappointment, SB chair to retire in 2027 Almere, The Netherlands December 8, 2025, 6:00 p.m. CET The Supervisory Board (SB) of ASM International N.V. (Euronext Amsterdam: ASM) announced today that it intends to reappoint Mr. Hichem M’Saad for a second term, for four years, as member of the Management Board and as CEO. It also intends to reappoint Supervisory Board Member Mr. Marc de Jong for a new term of two years. Supervisory Board Chair Ms. Pauline van der Meer Mohr has expressed her intention to retire as per the Annual General Meeting (AGM) 2027, w...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 8 December 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 1 December 2025 up to and including 5 December 2025 a total of 178,442 shares were repurchased on exchange at an average price of € 70.02. During the same period, 178,129 ...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
HEINEKEN appoints new regional President Americas Amsterdam, 5 December 2025 - Heineken N.V. (HEINEKEN) today announces that it has appointed Alex Carreteiro as Regional President Americas, and member of the HEINEKEN Executive Team, as per 1 March 2026. Alex, currently CEO of PepsiCo Brazil & South Cone Foods Business, succeeds Marc Busain, who left HEINEKEN on 1 October 2025.Alex CarreteiroAlex joins HEINEKEN from PepsiCo, where, as the CEO of PepsiCo Brazil & South Cone Foods business, he is responsible for 16,000 employees and 10 factories across Brazil, Chile, Argentina, Uruguay, and Pa...
UCB announced an additional upgrade to its FY25 financial guidance, where it now expects revenue to exceed € 7.6b, representing +24% y/y (previously at least € 7b), and adj. EBITDA margin to be higher than 31% (previously at least 30%). This is the company's second guidance upgrade this year and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS, as well as a favourable payer m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.